BioSpace News Archive

Johnson & Johnson’s radiopharma candidate JNJ-6420 returned mixed results in an early-stage study, demonstrating strong biochemical and radiographic response but also resulting in four patient deaths.

Phase I/II data for Regeneron Pharmaceuticals’ costimulatory bispecific antibody were disappointing, with only one complete response when used as a combination treatment with Libtayo for solid tumors.

After selling off its oral TYK2 blocker to Takeda for $4 billion, Nimbus Therapeutics has posted strong early-stage data for its other clinical candidate, NDI-101150, in solid tumors.

Full data from the FLOW study show that Novo Nordisk’s top-selling GLP-1 receptor agonist semaglutide can significantly reduce the risk of death by 20% in diabetes patients with chronic kidney disease.

CEO Pascal Soriot on Tuesday heralded a “new era of growth” for AstraZeneca with plans to launch 20 new medicines in six years. He’s delivered before but can he do it again?

Aiming to compete in the lucrative weight-loss drug market, Zealand Pharma on Thursday posted topline results showing its dapiglutide led to only a slight weight reduction in low doses.

Amid shortages of its Mounjaro and Zepbound blockbuster drugs, Eli Lilly on Friday said it is investing an additional $5.3 billion in its production site in Lebanon, Indiana, to boost output of their active ingredient.

yner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 16,300 shares of the Company’s common stock at an exercise price per share of $16.28, which was the closing price on May 23, 2024, and restricted stock units to acquire a total of 8,150 shares of the Company’s common stock.

Rakovina Therapeutics Inc. announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company dated May 29, 2023, certain holders of 12.0 per cent unsecured convertible debentures of the Company have elected to receive common shares of the Company in lieu of cash in partial satisfaction of an aggregate total of approximately $91,000 interest payable to all holders of the Debentures on May 29, 2024.